US3798209A
(en)
*
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
US4328245A
(en)
*
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4410545A
(en)
*
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
US4409239A
(en)
*
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
US4797286A
(en)
*
|
1985-11-12 |
1989-01-10 |
Eli Lilly And Company |
Orally administerable sustained release pharmaceutical formulations
|
GB8719367D0
(en)
*
|
1987-08-15 |
1987-09-23 |
Wellcome Found |
Therapeutic compounds
|
US5705363A
(en)
*
|
1989-03-02 |
1998-01-06 |
The Women's Research Institute |
Recombinant production of human interferon τ polypeptides and nucleic acids
|
US5026687A
(en)
*
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
AU660925B2
(en)
*
|
1990-04-06 |
1995-07-13 |
Genelabs Technologies, Inc. |
Hepatitis C virus epitopes
|
US5372808A
(en)
*
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
TW224053B
(es)
*
|
1991-09-13 |
1994-05-21 |
Paul B Chretien |
|
US5676942A
(en)
*
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
GB9226729D0
(en)
*
|
1992-12-22 |
1993-02-17 |
Wellcome Found |
Therapeutic combination
|
DE69419244T2
(de)
*
|
1993-02-24 |
1999-10-14 |
Jui H Wang |
Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
|
AU688344B2
(en)
*
|
1993-07-19 |
1998-03-12 |
Mitsubishi-Tokyo Pharmaceuticals, Inc. |
Hepatitis C virus proliferation inhibitor
|
US5433951A
(en)
*
|
1993-10-13 |
1995-07-18 |
Bristol-Myers Squibb Company |
Sustained release formulation containing captopril and method
|
ES2174915T3
(es)
|
1993-11-10 |
2002-11-16 |
Enzon Inc |
Productos de conjugacion mejorados de un interferon con un polimero.
|
US5951974A
(en)
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
DE4415539C2
(de)
*
|
1994-05-03 |
1996-08-01 |
Osama Dr Dr Med Omer |
Pflanzen mit virustatischer und antiviraler Wirkung
|
DE4432623A1
(de)
*
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
US5738846A
(en)
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5783846A
(en)
*
|
1995-09-22 |
1998-07-21 |
Hughes Electronics Corporation |
Digital circuit with transistor geometry and channel stops providing camouflage against reverse engineering
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US5980884A
(en)
*
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
WO1997032018A2
(en)
*
|
1996-02-29 |
1997-09-04 |
Immusol, Inc. |
Hepatitis c virus ribozymes
|
US5633388A
(en)
*
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
*
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
GB9609932D0
(en)
*
|
1996-05-13 |
1996-07-17 |
Hoffmann La Roche |
Use of IL-12 and IFN alpha for the treatment of infectious diseases
|
US5891874A
(en)
*
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US5837257A
(en)
*
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
JP3927630B2
(ja)
|
1996-09-27 |
2007-06-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウイルス感染症の予防・治療剤
|
US5922757A
(en)
*
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
PL194025B1
(pl)
|
1996-10-18 |
2007-04-30 |
Vertex Pharma |
Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
US6004933A
(en)
*
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
CZ293248B6
(cs)
*
|
1997-06-30 |
2004-03-17 |
Merz Pharma Gmbh & Co. Kgaa |
1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi
|
DE69827956T2
(de)
|
1997-08-11 |
2005-04-14 |
Boehringer Ingelheim (Canada) Ltd., Laval |
Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
|
DE69810822T2
(de)
|
1997-09-21 |
2003-11-20 |
Schering Corp |
Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infection
|
US5981709A
(en)
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US6350458B1
(en)
*
|
1998-02-10 |
2002-02-26 |
Generex Pharmaceuticals Incorporated |
Mixed micellar drug deliver system and method of preparation
|
KR100954390B1
(ko)
|
1998-02-25 |
2010-04-26 |
에모리 유니버시티 |
2'-플루오로뉴클레오사이드
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
KR100694345B1
(ko)
|
1998-05-15 |
2007-03-12 |
쉐링 코포레이션 |
리바비린 및 인터페론 알파를 포함하는, 만성 c형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
|
EP1087778B1
(en)
|
1998-06-08 |
2005-10-26 |
F. Hoffmann-La Roche Ag |
Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
|
US6171615B1
(en)
*
|
1998-07-06 |
2001-01-09 |
Gattefoss{acute over (e)} |
Sustained release theophylline formulations, excipient systems and methods of production
|
US6323180B1
(en)
*
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
ES2255295T3
(es)
|
1998-08-10 |
2006-06-16 |
Idenix (Cayman) Limited |
2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b.
|
AR021876A1
(es)
|
1998-12-18 |
2002-08-07 |
Schering Corp |
Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
|
CA2389745C
(en)
|
1999-11-04 |
2010-03-23 |
Shire Biochem Inc. |
Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
|
SK11922002A3
(sk)
|
2000-02-18 |
2003-06-03 |
Shire Biochem Inc. |
Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
|
ES2319732T3
(es)
|
2000-04-13 |
2009-05-12 |
Pharmasset, Inc. |
Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EP1736478B1
(en)
|
2000-05-26 |
2015-07-22 |
IDENIX Pharmaceuticals, Inc. |
Methods and compositions for treating flaviviruses and pestiviruses
|
MY141594A
(en)
|
2000-06-15 |
2010-05-14 |
Novirio Pharmaceuticals Ltd |
3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
|
EP1301527A2
(en)
|
2000-07-21 |
2003-04-16 |
Corvas International, Inc. |
Peptides as ns3-serine protease inhibitors of hepatitis c virus
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
MXPA03000626A
(es)
|
2000-07-21 |
2004-07-30 |
Schering Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
PT1411954E
(pt)
|
2000-10-18 |
2011-03-16 |
Pharmasset Inc |
Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
|
WO2002032414A2
(en)
|
2000-10-18 |
2002-04-25 |
Schering Corporation |
Ribavirin-pegylated interferon alfa hcv combination therapy
|
BR0115447A
(pt)
|
2000-11-20 |
2005-10-18 |
Bristol Myers Squibb Co |
Inibidores de tripeptìdeo de hepatite c
|
KR20030091946A
(ko)
|
2000-12-12 |
2003-12-03 |
쉐링 코포레이션 |
C형 간염 바이러스의 ns3-세린 프로테아제억제제로서의 디아릴 펩티드
|
WO2002048116A2
(en)
|
2000-12-13 |
2002-06-20 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
WO2002048157A2
(en)
|
2000-12-13 |
2002-06-20 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
|
AU2002232660A1
(en)
|
2000-12-15 |
2002-06-24 |
Pharmasset Ltd. |
Antiviral agents for treatment of flaviviridae infections
|
EP1539188B1
(en)
|
2001-01-22 |
2015-01-07 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US6825201B2
(en)
*
|
2001-04-25 |
2004-11-30 |
Bristol-Myers Squibb Company |
Indole, azaindole and related heterocyclic amidopiperazine derivatives
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
ITMI20021399A1
(it)
|
2002-06-25 |
2003-12-29 |
Nicox Sa |
Inibitori della cicloossigenasi 2
|
AU2003247084B9
(en)
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
MXPA04012802A
(es)
|
2002-06-28 |
2005-04-19 |
Idenix Cayman Ltd |
Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
|
WO2004014364A1
(en)
|
2002-08-07 |
2004-02-19 |
Idenix (Cayman) Limited |
Substituted phenylindoles for the treatment of hiv
|
CA2583409C
(en)
|
2004-09-17 |
2014-06-17 |
Idenix Pharmaceuticals, Inc. |
Phospho-indoles as hiv inhibitors
|
CA2623678A1
(en)
|
2005-09-29 |
2007-04-05 |
Repros Therapeutics Inc. |
Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
|
KR20090077813A
(ko)
|
2006-09-29 |
2009-07-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
Hiv 억제제로서의 거울상이성질체적으로 순수한 포스포인돌
|